ZYME zymeworks.com: Enterprise Value to EBITDA Ratio
Zymeworks Inc. (ZYME) minimizes dependency risks through the effective delegation of clinical trials to external CRO networks, as evidenced by the company's EV/EBITDA ratio. The value 0.00 captures the current state of this parameter. An asset-light model ensures supply stability by outsourcing drug production to contract manufacturing organizations, while the high value of licenses for innovative antibodies enables the company to attract multi-billion dollar payments from strategic partners.
Summary analytical data breakdowns for zymeworks.com (ZYME)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Zymeworks Inc.|ZYME - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Zymeworks|ZYME - Company Aggregate Debts|Debt to Book Capitalization Ratio Zymeworks Biopharmaceuticals|ZYME - Company Long-Term Indebtedness|Company Short-Term Debt Zymeworks|Quick Liquidity Indicator zymeworks.com
- financial results and valuation multiples details:
ZYME - Annual Net Income|Future Profit Zymeworks Inc.|ZYME - Market Price to Net Income Ratio|Forward P/E Multiple Zymeworks Inc.|ZYME - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Zymeworks Biopharmaceuticals|ZYME - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Zymeworks|ZYME - Earnings per share for the trailing year|Quarterly EPS earnings growth zymeworks.com|ZYME - Earnings growth in current year|Net earnings per share growth forecast for next year Zymeworks Inc.
Fundamental company analysis:ZYME (Zymeworks Corp)
This ratio compares the total enterprise value of Zymeworks Inc. (ZYME) with its EBITDA, allowing for an assessment of the actual debt load and cash flow generation efficiency. Given the costs of retaining scarce immunologists and bioinformaticians, the EV/EBITDA multiple trend serves as an indicator of the business's resilience to human capital expenditures amid fierce competition.
Competitor analysis for Zymeworks Inc.
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|TNGX: EV/EBITDA Multiple|IOVA - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immatics Corp|Enterprise Value to EBITDA Ratio Xencor Inc. (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics (CMPX)|Enterprise Value to EBITDA Ratio replimune.com REPL|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio NEXI|TSBX (turnstonebio.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx
